It has demonstrated significant clinical activity in patients with metastatic melanoma, renal cell carcinoma, microsatellite instable colorectal cancer and non-small cell lung cancer and response rates are higher compared to single agent anti-PD-1 therapy. Here, RPL17 is linked to hereditary clear cell renal cell carcinoma.